Secondary Prevention of Atrial Fibrillation (Impact of Renin-Angiotensin-Aldosterone System Inhibition)
In the present application, we propose to refine and extend current insight into AAF mechanism and therapy by examining the importance of pharmacologic RAAS inhibition, ACE genotype, and their interaction in secondary AF prevention. We have 3 specific aims:
- To confirm that RAAS inhibition therapy reduces the incidence of AF recurrence.
- To test the hypothesis that the incidence of AF recurrence in the absence of RAAS inhibition therapy is higher among patients with the D allele.
- To explore the hypothesis that RAAS inhibition therapy is more effective for preventing AF recurrence in patients with the DD genotype than in those with DI or II genotypes.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- UPMC CVI
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects must be in atrial fibrillation confirmed by 12 lead EKG.
- blood pressure > 90 mmHg
- Patient without cardiopulmonary symptoms
- 18+ years of age
Exclusion Criteria:
- Contraindiction to warfarin
- Recent (within 6 months) MI or cardiac revascularization
- Recent (within 6 months) CVA or TIA
- NYHA Class IV CHF
- Active thyroid disease
- Major hepatic dysfunction
- Renal dysfunction (>2 mg/dL)
- Hyperkalemia (>4.6 mEq/L)
- Hyponatremia (<130 mEq/L)
- Currently taking a Vaughn-Williams Type I or III antiarrhythmic drug
- History of ARB intolerance
- Contraindication to ARB therapy
- Pregnancy
- Female of childbearing age
- Age < 18 years of age
- Inability to give informed consent
- Other medical conditions calling 1 year survival into question
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: A Group 1 no drug
Patients who have not taken ACE/ARB, randomized to no drug.
|
none, no drug
|
|
Experimental: A Group 2
Patients who have not taken ACE/ARB, randomized to take cozaar.
|
start cozaar
|
|
Experimental: B
Patients currently taking ACE/ARB will have their prescription changed to cozaar.
|
continue cozaar
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
AF burden
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 0507061
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.